{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T15:50:24Z","timestamp":1781279424257,"version":"3.54.1"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Achieving functional cure of chronic hepatitis B (CHB), characterized by the loss of HBV DNA and HBsAg, remains challenging in adults but demonstrates higher success rates in children. Elucidating the factors influencing HBsAg loss in pediatric patients is crucial for optimizing treatment strategies. This study aimed to evaluate the predictive value of HBeAg titer dynamics for HBsAg clearance in pediatric CHB and develop a predictive model incorporating these dynamics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Material and methods<\/jats:title><jats:p>This retrospective cohort study analyzed 119 children aged 1\u201318 years with CHB treated with nucleos(t)ide analogues. Patient outcomes were evaluated using two independent classification approaches: HBsAg loss status and age stratification (\u22646 vs. &amp;gt;6 years). Treatment response was assessed through longitudinal HBeAg titer measurements during the first 12 months. Based on identified predictors, a logistic regression model was developed incorporating age and HBeAg titer dynamics to predict HBsAg clearance probability.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study population exhibited a median age of 6.2 years. Factors associated with HBsAg loss encompassed younger age, female sex, and absence of breakthrough. In multivariate analysis, younger age was identified as the only significant factor. The cumulative HBsAg loss rate demonstrated markedly higher values in the \u22646 years group (Hazard ratio 7.69). HBeAg titer decline exhibited significantly steeper trajectories in the HBsAg loss group. The developed predictive model, \u201cLog Odds\u2009=\u2009\u22121.182\u2009+\u20090.308\u2009\u00d7\u2009log_reduction\u22120.205\u2009\u00d7\u2009age\u201d, demonstrated good performance with high accuracy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Early HBeAg titer dynamics combined with age at treatment initiation may serve as useful predictors of HBsAg clearance in pediatric CHB. Our predictive model, utilizing readily available semi-quantitative HBeAg measurements, could potentially assist clinicians in therapeutic decision-making and individualized treatment strategies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2025.1539300","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T05:50:31Z","timestamp":1743659431000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Predictive value of HBeAg titer dynamics for HBsAg clearance in pediatric chronic hepatitis B"],"prefix":"10.3389","volume":"13","author":[{"given":"Sukjin","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Hyun","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keumoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Younghae","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naeun","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo Rim","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung-Ho","family":"Choe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.antiviral.2013.01.006","article-title":"Chronic hepatitis B: what should be the goal for new therapies?","volume":"98","author":"Block","year":"2013","journal-title":"Antiviral Res"},{"key":"B2","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3350\/kjhep.2009.15.2.168","article-title":"Comparison of lamivudine-induced HBsAg loss rate according to age in children with chronic hepatitis B","volume":"15","author":"Kim","year":"2009","journal-title":"Korean J Hepatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s12072-023-10631-9","article-title":"Functional cure is associated with younger age in children undergoing antiviral treatment for active chronic hepatitis B","volume":"18","author":"Zhang","year":"2024","journal-title":"Hepatol Int"},{"key":"B6","doi-asserted-by":"publisher","first-page":"405","DOI":"10.14218\/JCTH.2021.00142","article-title":"Clinical predictors of functional cure in children 1\u20136 years-old with chronic hepatitis B","volume":"10","author":"Pan","year":"2022","journal-title":"J Clin Transl Hepatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/01.mpg.0000243439.47334.4e","article-title":"Long-term therapeutic efficacy of lamivudine compared with interferon-alpha in children with chronic hepatitis B: the younger the better","volume":"44","author":"Choe","year":"2007","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B8","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.jhep.2013.05.016","article-title":"Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines: consensus of an expert panel on behalf of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition","volume":"59","author":"Sokal","year":"2013","journal-title":"J Hepatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s12072-021-10239-x","article-title":"APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy","volume":"15","author":"Lau","year":"2021","journal-title":"Hepatol Int"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.4254\/wjh.v8.i34.1511","article-title":"On-treatment quantitative hepatitis B e antigen predicted response to nucleos(t)ide analogues in chronic hepatitis B","volume":"8","author":"Gao","year":"2016","journal-title":"World J Hepatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1002\/hep.24221","article-title":"Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir","volume":"53","author":"Lee","year":"2011","journal-title":"Hepatology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e7766","DOI":"10.1097\/MD.0000000000007766","article-title":"Serum HBeAg and HBV DNA levels are not always proportional and only high levels of HBeAg most likely correlate with high levels of HBV DNA: a community-based study","volume":"96","author":"Chen","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3343\/lmo.2019.9.4.210","article-title":"Result patterns and characteristics of HBeAg and HBV DNA in patients with chronic hepatitis B","volume":"9","author":"Choi","year":"2019","journal-title":"Lab Med Online"},{"key":"B14","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/apt.17667","article-title":"Age at treatment initiation predicts response in children with chronic hepatitis B","volume":"58","author":"Wu","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1111\/jvh.13598","article-title":"Long-term benefits of interferon-\u03b1 therapy in children with HBeAg-positive immune-active chronic hepatitis B","volume":"28","author":"Wang","year":"2021","journal-title":"J Viral Hepat"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.14218\/jcth.2023.00014","article-title":"Functional cure of chronic hepatitis B with antiviral treatment in children having high-level viremia and normal or mildly elevated serum aminotransferase","volume":"11","author":"Li","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1053\/j.gastro.2012.06.009","article-title":"Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B","volume":"143","author":"Kennedy","year":"2012","journal-title":"Gastroenterology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/s12072-023-10597-8","article-title":"Why is the functional cure rate of young children with chronic hepatitis B receiving antiviral therapy considerably high?","volume":"18","author":"Wang","year":"2024","journal-title":"Hepatol Int"},{"key":"B19","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1053\/j.gastro.2020.04.019","article-title":"Effects of hepatitis B surface antigen on virus-specific and global T cells in patients with chronic hepatitis B virus infection","volume":"159","author":"Le Bert","year":"2020","journal-title":"Gastroenterology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3748\/wjg.v20.i2.401","article-title":"Then and now: the progress in hepatitis B treatment over the past 20 years","volume":"20","author":"Halegoua-De Marzio","year":"2014","journal-title":"World J Gastroenterol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.3346\/jkms.2018.33.e63","article-title":"A multicenter study of the antiviral efficacy of entecavir monotherapy compared to lamivudine monotherapy in children with nucleos(t)ide-na\u00efve chronic hepatitis B","volume":"33","author":"Lee","year":"2018","journal-title":"J Korean Med Sci"},{"key":"B22","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jfma.2013.02.001","article-title":"Hepatitis B viral factors and treatment responses in chronic hepatitis B","volume":"112","author":"Lin","year":"2013","journal-title":"J Formos Med Assoc"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.3346\/jkms.2018.33.e11","article-title":"Antiviral efficacy of tenofovir monotherapy in children with nucleos(t)ide-naive chronic hepatitis B","volume":"33","author":"Choe","year":"2018","journal-title":"J Korean Med Sci"},{"key":"B24","doi-asserted-by":"publisher","first-page":"5985","DOI":"10.1128\/JVI.76.12.5985-5992.2002","article-title":"Hepatitis B virus of genotype B with or without recombination with genotype C over the precore region plus the core gene","volume":"76","author":"Sugauchi","year":"2002","journal-title":"J Virol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3748\/wjg.v13.i1.14","article-title":"Hepatitis B virus taxonomy and hepatitis B virus genotypes","volume":"13","author":"Schaefer","year":"2007","journal-title":"World J Gastroenterol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3350\/kjhep.2009.15.2.140","article-title":"Distribution of hepatitis B virus genotypes in Korea","volume":"15","author":"Cho","year":"2009","journal-title":"Korean J Hepatol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"336","DOI":"10.21037\/atm.2016.09.06","article-title":"Treatment strategies according to genotype for chronic hepatitis B in children","volume":"4","author":"Man Cho","year":"2016","journal-title":"Ann Transl Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/rmv.1885","article-title":"The clinical implications of hepatitis B virus genotypes and HBeAg in pediatrics","volume":"26","author":"Kramvis","year":"2016","journal-title":"Rev Med Virol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.3346\/jkms.2018.33.e69","article-title":"What are the main differences in the treatment of chronic hepatitis B between Korean children and adults?","volume":"33","author":"Choe","year":"2018","journal-title":"J Korean Med Sci"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1539300\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T05:50:32Z","timestamp":1743659432000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1539300\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":29,"alternative-id":["10.3389\/fped.2025.1539300"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1539300","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,3]]},"article-number":"1539300"}}